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Characterization of a Computationally Designed Water-Soluble Human μ
Opioid Receptor Variant Using X-ray Structural Information
Abstract
Background
The recent X-ray crystal structure of the murine μ opioid receptor (MUR) allowed us to reengineer a
previously designed water-soluble variant of the transmembrane portion of the human MUR (wsMUR-TM).
Methods
The new variant of water soluble MUR (wsMUR-TM_v2) was engineered based upon the murine MUR
crystal structure. This novel variant was expressed in E. coliand purified. The properties of the receptor were
characterized and compared with those of wsMUR-TM.
Results
Seven residues originally included for mutation in the design of the wsMUR-TM, were reverted to their native
identities. wsMUR-TM_v2 contains 16% mutations of the total sequence. It was overexpressed and purified
with high yield. Although dimers and higher oligomers were observed to form over time, the wsMUR-TM_v2
stayed predominantly monomeric at concentrations as high as 7.5 mg/ml in buffer within a 2-month period.
Its secondary structure was predominantly helical and comparable with those of both the original wsMUR-
TM variant and the native MUR. The binding affinity of wsMUR-TM_v2 for naltrexone (Kd ~ 70 nM) was in
close agreement with that for wsMUR-TM. The helical content of wsMUR-TM_v2 decreased cooperatively
with increasing temperature, and the introduction of sucrose was able to stabilize the protein.
Conclusions
A novel functional wsMUR-TM_v2 with only 16% mutations was successfully engineered, expressed in E. coli
and purified based on information from the crystal structure of murine MUR. This not only provides a novel
alternative tool for MUR studies in solution conditions, but also offers valuable information for protein
engineering and structure function relationships.
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Abstract
Background—The recent X-ray crystal structure of the murine μ opioid receptor (MUR)
allowed us to reengineer a previously designed water-soluble variant of the transmembrane
portion of the human MUR (wsMUR-TM).
Methods—The new variant of water soluble MUR (wsMUR-TM_v2) was engineered based
upon the murine MUR crystal structure. This novel variant was expressed in E. coli and purified.
The properties of the receptor were characterized and compared with those of wsMUR-TM.
Results—Seven residues originally included for mutation in the design of the wsMUR-TM, were
reverted to their native identities. wsMUR-TM_v2 contains 16% mutations of the total sequence.
It was overexpressed and purified with high yield. Although dimers and higher oligomers were
observed to form over time, the wsMUR-TM_v2 stayed predominantly monomeric at
concentrations as high as 7.5 mg/ml in buffer within a 2-month period. Its secondary structure was
predominantly helical and comparable with those of both the original wsMUR-TM variant and the
native MUR. The binding affinity of wsMUR-TM_v2 for naltrexone (Kd ~ 70 nM) was in close
agreement with that for wsMUR-TM. The helical content of wsMUR-TM_v2 decreased
cooperatively with increasing temperature, and the introduction of sucrose was able to stabilize the
protein.
Conclusions—A novel functional wsMUR-TM_v2 with only 16% mutations was successfully
engineered, expressed in E. coli and purified based on information from the crystal structure of
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murine MUR. This not only provides a novel alternative tool for MUR studies in solution
conditions, but also offers valuable information for protein engineering and structure function
relationships.
Introduction
The G-protein-coupled receptor (GPCR) superfamily contains many major pharmacological
targets.1 The study of the molecular mechanisms of GPCRs is hampered by limited
information on structure-function relationships, the difficulties of working with membrane
proteins, various conformational states of the receptors, and the complexity in the
mechanisms of selectivity and activation. Solving the crystal structures of GPCRs is a major
scientific and technologic undertaking and often requires substantial molecular engineering.2
Revealing the crystal structures of the four major opioid receptors has been a major
milestone in opioid related research and drug development.3–6
From the opioid family, the μ opioid receptor (MUR) is clinically important since it is target
of opioid analgesics. MUR is a class-A GPCR widely expressed in the central nervous
system, and its signaling pathways are relevant in mediating analgesia, sedation, and
euphoria. Despite the recent advances, the detailed mechanisms of MUR activation and
related protein dynamics are still missing due to the many technical limitations including the
difficulty in obtaining large quantities of the functional receptor and the inherent low
stability when these proteins are isolated from the membrane environment.
To overcome the difficulty of studying the MUR in a lipid environment, we successfully
applied computational protein design to create the first version of a water-soluble variant of
the human MUR (wsMUR-TM). The protein was expressed in E. coli and retained structural
and functional features consistent with those of the native MUR.7 wsMUR-TM was
engineered using a comparative (homology) model based on the crystal structures of human
β2 adrenergic receptor and bovine rhodopsin.7 Although the homology model of the human
MUR superimposed well with the crystal structure of murine MUR overall (root-mean-
square deviation of the Cα atoms = 2.60 Å),8 there are several structural differences, which
would impact the selection of sites for designing to confer water solubility. Such differences
are expected since there is only 27% sequence similarity between 288-residue
transmembrane portions of the human β2 adrenergic receptor and the human MUR7. The
murine MUR crystal structure provides critical information to locate the mutated positions
in wsMUR-TM since the sequence similarity between the human and the mouse MURs is
94% for the entire sequence and 99% for the segment solved in the crystal structure. Such
critical information is used in the present study to reengineer the wsMUR-TM by
eliminating mutations that may be unnecessary to confer water solubility and avoid toxicity
to the bacterial expression system. This restoration of native amino acid identities allow us
to explore possible deleterious expression, solubility, structure and function, and probe the
sensitivity of structural and functional features of the designed variants to the choice of
template structure. The resulting watersoluble variant (wsMUR-TM_v2) was characterized;
structural and functional properties were compared to that of wsMUR-TM. Important
findings regarding the stability of these water-soluble analogs were analyzed in detail as
well as their relevance as suitable surrogates to study properties of the native MUR.
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Materials and Methods
The SNAP-Lumi4-Tb-μ-opioid receptor (Cisbio Bioassays, Bedford, MA), which is
composed of a SNAP-tag® enzyme labeled with terbium cryptate (Lumi4®-Tb, a long
lifetime fluorescence resonance energy transfer donor) fused at the N-terminus of a native
MUR, was expressed on HEK293 cells. Red-naltrexone, an analog of naltrexone, the MUR
antagonist that contains the d2 dye, was also obtained from Cisbio Bioassays for receptor
affinity determination. All other chemicals with high purity were obtained from Sigma-
Aldrich (St. Louis, MO) except when specified otherwise.
Structural geometrical analysis and wsMUR re-engineering
The structure of the murine MUR (PDB accession code: 4DKL)6 was obtained from the
protein data bank (PDB)a). The sequence of the previously designed water-soluble variant
was mapped onto the crystal structure of the murine MUR and structural analysis was
performed using Visual Molecular Dynamics program(Beckman Institute, Urbana, IL)9 and
PyMOL (Version 1.3, Schrödinger, LLCb)). Residue positions selected to be mutated to the
native human residue identities were identified based on their relative location in the context
of the murine mu opioid crystal structure. Herein the Ballesteros and Weinstein indexing is
adopted as a superscript in identifying particular residue positions in the receptors.10
Protein expression and purification
The synthetic complementary deoxyribonucleotides encoding of the wsMUR-TM (previous
version reported7), wsMUR-TM_v2 (the modified new version) were constructed by
DNA2.0 Inc. (Menlo Park, CA) and GenScript Inc. (Piscataway, NJ), respectively. The
sequences were subcloned between the NdeI and XhoI restriction sites of the expression
plasmid pET-28b(+) (EMD/Novagen, Billerica, MA). This cloning strategy resulted in
placement of a His-tag at the amino terminus of the protein and was not removed in
subsequent characterization. Protein expression using E. coli BL21(DE3) cells (EMD/
Novagen) and purification were performed as described previously.7
Mass spectrometry
The purified proteins were run in a sodium dodecyl sulfate (SDS) polyacrylamide gel
electrophoresis (PAGE) gel. The protein band of the expected molecular weight was excised
and digested with trypsin for verification purposes. NanoLC proteomics experiments were
run at 200 nL/min for 60 min with gradient elution by injecting digested peptides into a
nano-LC mass spectrometry (10 cm C18 capillary column) to be separated by Eksigent.
Separated peptides were sprayed into LTQ by Nanospray (Thermo Fisher Scientific, MA).
Xcalibur (Xcalibur, Inc., Arlington, VA) was used for raw data acquisition. Sequest
(Thermo Fisher Scientificc)) was used to search the database Uniprotd). Scaffold 2.6
(Proteome Software, Inc., Portland, OR) was used to analyze the data quantitatively.
a)http://www.rcsb.org/pdb/explore/explore.do?structureId=4DKL; last date accessed April 19, 2014.
b)http://www.pymol.org/; last date accessed April 19, 2014.
c)http://fields.scripps.edu/sequest; last date accessed April 19, 2014.
d)http://www.uniprot.org; last date accessed April 19, 2014.
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High-resolution atomic force microscopy
Tapping mode atomic force microscopy in air (MFP-3D, Asylum Research, CA) was used to
visualize the protein particles under various solution conditions as we described
previously.11 Similar technology has been used to observe Alzheimer β-amyloid oligomers
and monomers in solution conditions.12 To prepare a sample, protein solution was applied
deposited onto the surface of an oxidized silicon wafer and allowed to incubate in a humid
atmosphere for 1 h. The sample was then washed in two separate baths of deionized water
for 3 min each in order to remove weakly bound protein molecules. From this series of
experiments, we tested whether the protein remained predominantly in a monomeric state in
the buffer condition.
Circular dichroism and thermal stability
Circular dichroism was used to determine the secondary structure content and the
thermostability of the protein as described previously.13 Chirascan circular dichroism
Spectrometer (AppliedPhotophysics Limited, Leatherhead, United Kingdom) was used with
1 mm path length and a scan speed of 1 nm/s. The experiments were performed at least three
times to ensure repeatability of the experiments. Data sets were recorded three times and
averaged to increase the signal-to-noise ratio. The CDNN circular dichroism spectra
deconvolution software14 was utilized to determine the content of the secondary structure.
Circular dichroism spectra for wsMUR-TM_v2 were also determined from 10 °C to 90 °C
with increments of 2 °C per min (6 µM of the receptor in 5 mM sodium phosphate, pH=7.0)
in the absence and presence of 1 M sucrose. The effect of sucrose on the helical content of
the wsMUR-TM_v2 was also tested in the presence and absence of 3 M urea. The cuvette
was sealed with oil to avoid errors from evaporation. The helical content is plotted against
temperature using GraphPad Prism (v 5.02, GraphPad Software, Inc., La Jolla, CA).
Interaction with naltrexone: binding assay and docking calculations
To determine the binding affinities of the modified new protein constructs, we utilized the
same homogeneous time-resolved fluorescence methodology described in our previous
report7. Briefly, Tag-lite ® MUR cells (Cisbio Bioassays, Bedford, MA) in culture medium
were dispensed in white low-volume microplates (384-well, Greiner Bio-One North
America, Monroe, NC) at 3700 cells/10 µL/well Tag-lite μ opioid labeled cells with 60 nM
of Tag-lite opioid receptors red-naltrexone, 5 µL of the engineered MUR with 1:2 serial
dilutions from the µM to the nM range was added into the sample with the final volume of
20 µl. After incubation at room temperature for 2 h, homogeneous time-resolved
fluorescence signals were determined by FLUOstar plate reader (BMG, Cary, NC) with
excitation at 337 nm at 620 and 665 nm emission. The experiments were repeated at least
three times. Affinities for wsMURs were determined by fitting to concentration–responses
curves using the GraphPad Prism program (v 5.02, GraphPad Software, Inc., La Jolla CA).
To interpret the experimental ligand-binding data after the seven mutations were introduced,
docking calculations for the ligand naltrexone using the structure of the murine MUR
(4DKL)6 were carried out using the DockingServere) 15 as previously described16,17.
ehttp://www.dockingserver.com; last date accessed April 19, 2014.
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Affinity (grid) maps of 30×30×30 Å grid points with a spacing of 0.375 Å were used for the
docking calculations.
Statistical analysis
The shift of the thermostability curve is determined by comparing the temperature difference
where the normalized mean residue molar ellipticity is at 50%. Three repeats of data are
obtained and analyzed using the t test. The affinities are presented as mean ± one standard
deviation from three repeated measurements. The results were analyzed using GraphPad
Prism (version 5.02 Windows version). p-values smaller than 0.05 are considered
statistically significant.
Results
Structural analysis suggests candidate residues for back-mutation in water-soluble MUR
From a comparative structural analysis of wsMUR-TM and the murine crystal structure, five
positions (E1202.54, K1302.64, D2325.36, G3056.58, and K3066.59) were identified whose
variation could possibly disrupt either ligand binding or internal packing of amino acids (fig.
1A). Based on previous binding studies carried out in wsMUR-TM with a naltrexone analog,
we found no significant disruption in the binding capabilities of wsMUR-TM compared to
the native receptor. Nonetheless, native MUR also binds larger ligands, and these five
mutations in the vicinity of the orthosteric binding site could affect the receptor’s binding to
other ligands.7 In addition, two residues were mutated back to their native residue identities
based on structural considerations (E2976.50 and K3036.56). Position E2976.50 was originally
a proline residue in wsMUR-TM, and its presence could be important in retaining the right
geometry of transmembrane helix 6. At position K3036.56, the native isoleucine appears to
play an important role in the complementary packing of the transmembrane 5 and
transmembrane 6 helices (fig. 1A). None of the seven positions were directly in contact with
the beta-Funaltrexamine (β-FNA) ligand that was cocrystalized with murine MUR. These
seven residues in wsMUR-TM, located in the transmembrane helical core and near the
binding pocket, were mutated back to their native identities (E120T2.54, K130Y2.64,
D232N5.36, E297P6.50, K303I6.56, G305K6.58, and K306A6.59) to generate a modified new
analog denominated wsMUR-TM_v2 (fig. 1A and B).
Overexpression, purification, and verification of wsMURs
Both variants of the wsMURs expressed well and were isolated with high purity using nickel
affinity chromatography. There was no appreciable difference in the bacteria growth (as
monitored by optical density [OD]) and the yields of both variants (~20 mg/L of shake flask
culture). ~0.1% SDS was initially required to solubilize and purify the receptors. After
removing nonbound SDS via dialysis, both variants were soluble at ~7.5 mg/mL in a buffer
containing 130 mM NaCl, 20 mM sodium phosphate with a pH of 7.0 without appreciable
precipitation. A thick dark band in the SDS-PAGE presented in figure 2A belonged to
wsMUR-TM_v2, as confirmed by mass spectroscopy. The coverage of the identified peptide
segment was as high as 85%. One of the protein fragments of the wsMUR-TM_v2 variant,
identified by mass spectrometry, is presented in figure 2B. It is important to note that there
was a very faint band in the gel with a molecular weight corresponding to a dimer of the
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receptor (fig. 2A). This band was also studied by mass spectrometry and corroborated to be
the sequence of wsMUR-TM_v2, suggesting the potential existence of covalent dimer of the
protein.
Atomic force microscopy
From a series of atomic force microscopy experiments, we found that both wsMURs are
could be dispersed using buffer conditions and were predominantly monomeric (80~90%)
when freshly prepared within a 1-week period. Consistent with the observation in SDS-
PAGE, the existence of features whose heights are consistent with those of the dimer were
observed in the atomic force microscopy experiments. The receptor was observed to
aggregate as a function of time. 0.02% SDS and 5 mM 2-mercaptoethanol could reduce such
aggregation significantly. As indicated in figure 3A and B, 70% of the surface features are
ascribed to be monomeric for a 2-month old sample of wsMUR-TM_v2 in a buffer
condition of 20 mM sodium phosphate, 130 mM sodium chloride, 0.02% SDS, and 5 mM 2-
mercaptoethanol, pH=7.0.
Secondary structure content of wsMURs
The circular dichroism spectra of wsMUR-TM_v2 indicated predominantly helical structure
with a helical content of 57% estimated by the molar ellipticity over the range 205 to 260
nm. This value is consistent with similar measurements on wsMUR-TM (fig. 4). The helical
content of wsMUR-TM_v2 and wsMUR-TM is presented in table 1. Upon addition of 1 M
sucrose, no significant change in the helical content was observed. Also, the inclusion of 3
M urea reduced the helical content significantly but such reduction was restored by the
presence of 1 M sucrose (data not shown).
Thermal stability of wsMURs
As monitored by circular dichroism, wsMURs started to lose ellipticity with increasing
temperature and were nearly fully unfolded at 90 °C (fig. 5A). The thermal stability curve of
wsMUR-TM_v2 shifted to the left (lower temperature) by 5.8 ± 1.5 °C relative to the
wsMUR-TM (p = 0.007). It is important to note that the thermal stability curve shifted to
higher temperature significantly in the presence of sucrose (fig. 5B).
Interaction with opioid antagonist naltrexone
Naltrexone binding was monitored using a competitive time-resolved fluorescence
resonance energy transfer based assay with fluorescently labeled wild type MUR and a
naltrexone-derived antagonist. The ratio of fluorescence emission at 620 and 665 nm
decreased in a concentration-dependent manner with increasing concentrations of both
variants of wsMUR. There was no significant difference for the affinity with naltrexone for
both wsMURs (fig. 6). The Kd value for wsMUR-TM was similar to the previously reported
value (67 ± 4 nM), while the Kd value for wsMUR-TM_v2 was 70 ± 7 nM. Both values are
in closed agreement with values for native MUR reported using other techniques.7,18
To interpret the findings from the binding assay at a molecular level, docking calculations
were carried out using the mouse crystal structure and naltrexone. Docking calculation
results indicated that the naltrexone binding site overlapped well with that of the β-FNA as
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demonstrated in figure 7A. The consistency in the affinity values for both wsMURs could be
ascribed to the fact that there is no direct contact of any of the seven mutated residues with
the ligand naltrexone (fig. 7B).
Discussion
The crystal structure of the murine MUR complexed with the irreversible antagonist β-FNA6
provides valuable information to reengineer our previously designed water-soluble variant
wsMUR-TM.7 Based on structural analysis, seven positions in wsMUR-TM were returned
to their native residue identities. Residues were selected based upon their relative position to
the surface of the protein and the orthosteric binding pocket in the structure of the murine
MUR. The resulting protein, wsMUR-TM_v2, expressed well in E. coli and was purified in
large amounts sufficient to perform biophysical experiments without significant change in
the protein’s water solubility. Interestingly, while the affinity of the protein for naltrexone
did not change significantly, the thermostability of the protein decreased slightly. Addition
of the osmolyte sucrose increased the thermal stability of the protein significantly.
Computational design of wsMURs
In the quest to facilitate the characterization of different membrane proteins, computational
design has been used to engineer water-soluble variants of membrane proteins. Previously,
variants have been engineered of the potassium channel from Streptomyces lividans
(KcsA)19–21 and the transmembrane domain of the α1 subunit of the nicotinic acetylcholine
receptor (nAChR),22 with mutations ranging from 18% to 30% of the total number of
residues. In our first version of the water-soluble analog of the human MUR, wsMUR-TM,
18% of the residues (53 out of 288) was mutated. An important question that remained was
to what extent to which the number of mutations could be reduced without compromising
desired properties such as water solubility and protein production in E. coli. As we discussed
previously, the toxic effects of the human MUR to cell lines have limited the capability to
express the native receptor in this heterologous bacterial expression system.7 The
cytotoxicity of the native MUR is possibly a result of hydrophobic residues located within
the receptor’s transmembrane region, as mutations of mainly hydrophobic residues in the
designed water-soluble variants significantly reduced the cytotoxicity and facilitated over-
expression in E. coli. While we cannot conclude that all of the mutated residues in the
present study were required for high protein expression and formation of a variant with
structural and functional properties comparable to those observed in the native receptor, we
achieved the lowest number of mutations for any water-soluble variants we have designed so
far (16%, 46 mutated residues out of 288), an important technical achievement.
The production of a soluble and functional water-soluble MUR for its biophysical
characterization involves computationally redesigning the protein, and residues in the
transmembrane region are the focus. Mutating residues, including mutating redesigned sites
back to their native identities, could disrupt any of the steps associated with production of
native-like protein, including: cytotoxicity of the heterologous system (failure of
expression); protein purification; protein stability; water solubility; and receptor’s binding
properties. However, even after mutating seven residues located in transmembrane helical
Zhao et al. Page 7
Anesthesiology. Author manuscript; available in PMC 2015 October 01.
core of the receptor, the protein can still be over-expressed in E. coli and retains intrinsic
structural and binding features as a MUR. The protein variant created using a previously
created homology model alone (wsMUR-TM) and that created by an analysis of the
crystallographic murine receptor and restoration of wild-type identities at seven residues
(wsMUR-TM_v2) had essentially identical helical content and naltrexone affinities. The
information of the mutations introduced in wsMUR-TM_v2 offers additional structure-
sequence details to identify the features involved in cytotoxicity, solubility, and sequence-
structural- function relationship studies for MUR and other GPCRs in the same family.
These observations further confirm our previous finding that, at least for the GPCR family
of proteins, homology modeling can yield high quality structures suitable for the
computational design of water-soluble variants. While the properties of the two designed
proteins are similar, it is unclear whether there are significant tertiary structure differences.
Since both are water soluble that can be over expressed in E. coli, thus, they can be used as
parallel alternative tools to access sequence-structure-function relationships using nuclear
magnetic resonance in solution conditions, which is an ongoing effort within our group.
wsMURs oligomeric states in solution condition
Atomic force microscopy provides a very useful tool to evaluate our water-soluble proteins.
The data are consistent with previous work indicating that the engineered wsMURs are
soluble in buffer conditions and stay predominantly monomeric.7 Though the protein exists
largely in the monomeric form, the formation of oligomers, particularly dimers, is also
confirmed. The presence of different oligomeric states is consistent with the SDS-PAGE
electrophoresis data. It is known that the MUR can form SDS resistant dimers in living
organisms, and dimerization may play critical roles in physiological and pharmacological
functions of the receptor.23,24 This self-association appears not to be eliminated by the large
numbers of mutations involving exposed hydrophobic residues described in our study. Such
dimerization persists but is diminished in the presence of 5 mM of the reducing agent 2-
mercaptoethanol. The presence of SDS and 2-mercaptoethanol appear to reduce aggregation
to improve the overall shelf life of the protein sample. Using crystallography, we have
previously demonstrated that low concentrations of SDS do not change the protein structure
in the natural mammalian protein, apoferritin.25 Nonetheless, further studies are needed to
determine the extent to which the tertiary structure of the wsMUR is altered in such low
SDS concentrations. Further studies are also needed to eliminate SDS in the purification
process.
The structure and thermostability
The secondary structure of the modified new version wsMUR-TM_v2 is consistent with that
of the previously reported wsMUR-TM variant. As intended, the introduction of the
mutations K130Y2.64, K303I6.56, and K306A6.59 seem to induce better protein packing as
the helical content improved slightly in wsMUR-TM_v2 when compared with wsMUR-TM.
The remaining mutations could also play similar roles in improving the overall protein
packing of the new water-soluble variant. However, it is interesting to note that the thermal
stability curve of the modified new design shifted to lower temperature by 5 °C as compared
to that of the first version, suggesting slight decrease of the thermal stability. One possible
explanation is the reintroduction of a proline residue at position 2976.50. Although this
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mutation was intended to restore and facilitate interactions that stabilize the irregularities in
transmembrane helix 6, the helix propensity of proline is the lowest of all the amino acid
residues and in the absence of the lipid bilayer, this could decrease the thermal stability of
the protein.
With the exception of rhodopsin, GPCRs are generally unstable, one of the major obstacles
for structural function relationship studies.26 We recently demonstrated that the hydrophobic
molecule cholesterol improves the thermostability of the wsMUR-TM.7 It is critical to
identify a water-soluble compound that could be used to stabilize the protein
thermodynamically. Sucrose stabilizes some proteins and forces some unfolded protein to
folded states.27 Consistent with these reports, sucrose was able to restore the helical content
reduction due to presence of urea. Moreover, addition of 1 M sucrose increased the thermal
stability of wsMUR-TM_v2 significantly. This finding is critical for further structural and
functional studies of these opioid receptor analogs, since the addition of this osmolyte is able
to stabilize the protein without precipitation. Sucrose also does not generally interference
with protein nuclear magnetic resonance signals, which is desired for the study of the
receptor’s structure and dynamics in solution conditions.
Ligand Binding Properties of the wsMURs
In this study, we adopted the same methodology reported recently to quantify the affinity of
the wsMURs with naltrexone, a potent antagonist of MUR.7 The results indicated no
significant change in the affinity of wsMUR-TM_v2 relative to wsMUR-TM for naltrexone
despite the introduction of seven mutations in proximity to the binding pocket. These
findings are consistent with the observations that none of these residues have direct contact
with β-FNA in the murine crystal structure of the MUR. Additionally, our docking
calculations suggest that naltrexone binds in essentially the same binding pocket as the
morphian group of β-FNA. These findings corroborate our conclusions from our previous
report that demonstrated a close agreement of the naltrexone affinity of the wsMUR-TM
with that of the native MUR.
Conclusions and Future Directions
The study presented here demonstrated that available crystal structure allowed us to reliably
reduce number of mutated residues in the water-soluble variant wsMUR-TM_v2 without
affecting the protein production in E. coli, the affinity for naltrexone, and the solubility of
the protein in the buffer solution relative to its predecessor wsMUR-TM. However, the
thermostability study revealed that some of the mutated residues play important roles in the
protein stability, which is an important consideration for future mutagenesis studies and for
structure-function investigations. Sucrose could be an important alternative molecule to be
used to stabilize these water-soluble variants for structural studies. This study not only
provides a novel variant of water soluble MUR as a useful tool for MUR studies, but also
offers valuable information to engineer water-soluble versions of GPCR, a clinically
relevant membrane protein superfamily.
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Figure 1.
A) Rendering of a model based on the murine mu opioid receptor crystal structure. The side
chains of residues computationally designed to generate wsMUR-TM are rendered blue. The
root-mean-square deviation of the Cα atoms between this previous comparative model
model and the murine structure involving transmembrane domain residues is 2.60Å.8 The
designed positions selected to be mutated back to the human native identities are shown in
magenta (E120T2.54, K130Y2.64, D232N5.36, E297P6.50, K303I6.56, G305K6.58, and
K306A6.59, see Materials and Methods for description about Ballesteros and Weinstein
indexing.10 B) Sequences of the transmembrane domain of wild-type human μ opioid
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receptor (top) and the designed water-soluble variant wsMUR-TM (bottom) are displayed.
Highlighted in orange are the segments of the designed sequence (wsMUR-TM) identified
to be important to preserve protein expression. Seven residues that have been restored to
native identities are starred and colored in magenta. wsMUR-TM = first variant of the water-
soluble human μ opioid receptor transmembrane portion; wsMUR-TM_v2 = modified
(second) variant of the water-soluble human μ opioid receptor transmembrane portion; TM =
transmembrane; M/Z = mass-to-charge ratio.
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Figure 2.
Overexpression and verification of wsMUR-TM_v2. A) A sodium dodecyl sulfate
polyacrylamide gel electrophoresis for wsMUR-TM_v2 is shown, where lane 1 corresponds
to the MW standard, lane 2 to purified wsMUR-TM_v2. The band corresponding to the
molecular weight of wsMUR-TM_v2 is indicated by a red arrow. A faint band around twice
the molecular weight of wsMUR-TM_v2 is also noted (green arrow). Both bands were
excised for mass spectrometry and confirmation of protein identity. Each band was
identified as wsMUR-TM_v2 with around 85% coverage of the sequence. The faint band
represents the dimer of wsMUR-TM_v2. B) Representative mass spectrometry data for
fingerprinting of an identified peptide fragment is displayed and data are consistent with the
following subsequence (NAKEENEKNWKLSSEIGKPVEK). wsMUR-TM_v2 = modified
(second) variant of the water-soluble human μ opioid receptor transmembrane portion; M/Z
= mass-to-charge ratio.
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Figure 3.
A) Atomic force microscopy image of a sample wsMUR-TM_v2 after stored at 4 °C for
about 2 months. Protein concentration is 7.5 mg/mL. Buffer is 20mM sodium phosphate,
130mM NaCl, 0.02% sodium dodecyl sulfate, 5mM 2ME, pH=7.0. Monomer, dimer, and
large aggregates are present. B) Histogram of the feature of the protein in the solution. The
estimated number of features present on surface consistent with the dimensions of the
monomer is ~70%. wsMUR-TM = first variant of the water-soluble human μ opioid receptor
transmembrane portion; wsMUR-TM_v2 = modified (second) variant of the water-soluble
human μ opioid receptor transmembrane portion.
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Figure 4.
Circular dichroism spectra of the wsMUR-TM_v2 compared with the originally designed
wsMUR-TM at buffer condition of 5 mM sodium phosphate, pH = 7.0 at temperature of 25
°C. The two proteins displayed similar spectra. Estimates of helical content obtained using
the two spectra are presented in table 1. MRME, mean residue molar ellipticity; wsMUR-
TM_v2 = modified (second) variant of the water-soluble human mu opioid receptor
transmembrane portion.
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Figure 5.
Molar circular dichroism derived percentage of the original helical content (determined at
222 nm) of wsMUR-TM and wsMUR-TM_v2 in buffer solution (5 mM sodium phosphate,
pH = 7.0) as functions of the temperature. A) It demonstrated that wsMUR-TM is
thermodynamically more stable than wsMUR-TM_v2. B) The addition of sucrose stabilized
the wsMUR-TM_v2 as indicated by the significant rightward shift of the thermostability
curve. MRME = mean residue molar ellipticity; wsMUR-TM = first variant of the water-
soluble human μ opioid receptor transmembrane portion; wsMUR-TM_v2 = modified
(second) variant of the water-soluble human μ opioid receptor transmembrane portion.
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Figure 6.
Binding competition assay between the human μ opioid receptor expressed in HEK293 cells
and the μ opioid water-soluble variants. Inhibition of the native μ opioid receptor
constitutive signal from the interaction with naltrexone in the presence of increasing
concentrations of wsMUR-TMs in sodium phosphate buffer is demonstrated which is
essentially in a similar pattern, indicating a similar affinity of naltrexone for both of the
variants. The Kd values are 67 ± 4 nM for wsMUR-TM and 70 ± 7 nM for wsMUR-TM_v2.
The Kd value indicates the average value of three measurements. The error bars in the figure
are obtained as the standard deviation of three independent measurements. ΔF is used for the
comparison of different runs of the same assay which reflects the signal to background of
the assay. F=[(Ratiosample−Ratiobackgroud)/Ratiobackgroud](%). As we described previously
for the homogeneous time-resolved fluorescence binding assay,7 “Ratio” was the ratio of
fluorescence emission at 665 nm and 620 nm, and Kd values were determined by fitting the
dose–response curves using Prism (GraphPad Software, San Diego, CA).The Kd value
indicates the average value of three measurements. wsMUR-TM = first variant of the water-
soluble human μ opioid receptor transmembrane portion; wsMUR-TM_v2 = modified
(second) variant of the water-soluble human μ opioid receptor transmembrane portion.
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Figure 7. The relationship of the naltrexone with the mutated residues
A) Rendering of the murine μ opioid receptor. The seven residues that were mutated back to
their native residue identities are in magenta (E120T2.54, K130Y2.64, D232N5.36, E297P6.50,
K303I6.56, G305K6.58, and K306A6.59). The docking pose of naltrexone (yellow) overlaps
with the pose of β-Funaltrexamine (green). B) Similar view as (A) but with the protein
rendered in space filling representation. The docked posed of naltrexone (yellow) does not
directly contact any of the seven mutated positions (magenta).
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Table 1
Comparison of the Secondary Structure of the Two Variants of wsMURs
205–260 nm wsMUR-TM wsMUR-TM_v2
Helix 53.7% 55.6%
Antiparallel 4.6% 4.4%
Parallel 4.9% 4.6%
Beta-Turn 13.9% 13.6%
Others 22.9% 21.8%
wsMUR-TM = first variant of the water-soluble human μ opioid receptor transmembrane portion; wsMUR-TM_v2 = modified (second) variant of
the water-soluble human μ opioid receptor transmembrane portion. Buffer condition: 0.01% Sodium dodecyl sulfate, 5 mM sodium phosphate, pH
= 7.0 in room temperature.
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